Method of providing safe administration of adenoviral vectors encoding a zika virus antigen

Patent metadata

Field	Value
Publication number	US-10864263-B2
Application number	US-201816194868-A
Country	US
Kind code	B2
Filing date	Nov 19, 2018
Priority date	Nov 20, 2017
Publication date	Dec 15, 2020
Grant date	Dec 15, 2020

Abstract

Provided are methods for generating an immune response against a Zika virus in a human subject in need thereof. The methods comprise administering to the subject a pharmaceutical composition comprising adenoviral vectors encoding a Zika virus antigen and a pharmaceutically acceptable carrier.

First claim

It is claimed:

1. A method for generating an immune response against a Zika virus in a human subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising adenoviral vectors of the Ad26 serotype comprising a nucleic acid sequence encoding a Zika virus antigen, wherein the Zika virus antigen comprises the amino acid sequence of SEQ ID NO:2, and a pharmaceutically acceptable carrier, wherein about 5×1010 adenoviral vectors to about 1×1011 adenoviral vectors are administered per dose to the subject in need thereof, and wherein the pharmaceutical composition is administered in two doses to the human subject in a prime-boost regimen.

2. The method of claim 1 , wherein about 5×10 10 adenoviral vectors are administered per dose to the subject in need thereof.

3. The method of claim 1 , wherein about 1×10 11 adenoviral vectors are administered per dose to the subject in need thereof.

4. The method of claim 1 , wherein the pharmaceutical composition is administered via an intramuscular injection to the subject in need thereof.

5. The method of claim 1 , wherein the first and second dose of the pharmaceutical composition are administered to the human subject about four weeks, about eight weeks, about twelve weeks, about three months, about six months, about nine months, about one year, or about two years apart.

6. The method of claim 5 , wherein the first and second dose of the pharmaceutical composition are administered to the human subject about eight weeks apart.

Assignees

• Janssen Pharmaceuticals Inc
• Beth Israel Deaconess Medical Ct Inc

Inventors

• Barouch Dan
• Douoguih Macaya Julie
• Picchio Gaston Rafael

Classifications

• C12N2770/24134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N2710/10343

  viral genome or elements thereof as genetic vector · CPC title

• A61K39/12 Primary

  Viral antigens · CPC title

• A61P31/14

  for RNA viruses · CPC title

• A61K2039/6075

  Viral proteins · CPC title